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Background: Patients with chronic obstructive pulmonary disease (COPD) often suffer concomitant disorders that
worsen significantly their health status and vital prognosis. The pathogenic mechanisms underlying COPD
multimorbidities are not completely understood, thus the exploration of potential molecular and biological linkages
between COPD and their associated diseases is of great interest.
Methods: We developed a novel, unbiased, integrative network medicine approach for the analysis of the
diseasome, interactome, the biological pathways and tobacco smoke exposome, which has been applied to the
study of 16 prevalent COPD multimorbidities identified by clinical experts.
Results: Our analyses indicate that all COPD multimorbidities studied here are related at the molecular and
biological level, sharing genes, proteins and biological pathways. By inspecting the connections of COPD with their
associated diseases in more detail, we identified known biological pathways involved in COPD, such as
inflammation, endothelial dysfunction or apoptosis, serving as a proof of concept of the methodology. More
interestingly, we found previously overlooked biological pathways that might contribute to explain COPD
multimorbidities, such as hemostasis in COPD multimorbidities other than cardiovascular disorders, and cell cycle
pathway in the association of COPD with depression. Moreover, we also observed similarities between COPD
multimorbidities at the pathway level, suggesting common biological mechanisms for different COPD
multimorbidities. Finally, chemicals contained in the tobacco smoke target an average of 69% of the identified
proteins participating in COPD multimorbidities.
Conclusions: The network medicine approach presented here allowed the identification of plausible molecular
links between COPD and comorbid diseases, and showed that many of them are targets of the tobacco exposome,
proposing new areas of research for understanding the molecular underpinning of COPD multimorbidities.
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Multimorbidities, including cardiovascular diseases (CVD),
skeletal muscle weakness, osteoporosis, metabolic syn-
drome, depression and lung cancer, among others, are
highly prevalent in patients with chronic obstructive pul-
monary disease (COPD) [1-4] and contribute to worsen
their health-status and vital prognosis [4,5]. The pathogenic
mechanisms linking COPD and its concomitant diseases
are incompletely understood [6], but shared risk factors* Correspondence: lfurlong@imim.es
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article, unless otherwise stated.(tobacco smoking, physical inactivity, ageing) and COPD-
related specific mechanisms (systemic inflammation, tissue
hypoxia, abnormal protein metabolism) may potentially
contribute. It is also possible that COPD and its multimor-
bidities share genes, proteins and pathways that explain
their tendency to co-occur together in a particular patient
[7-9]. A systematic investigation of this "shared component
hypothesis" can provide insights to improve the prevention,
early diagnosis, prognosis and/or treatment of COPD mul-
timorbidities [9,10]. The new discipline of network medi-
cine offers a platform to systematically explore the
molecular complexity of a given disease with the potentialtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 The diseases analyzed in this study and their
corresponding number of UMLS Concept Unique
Identifiers (CUIs) and associated genes in DisGeNET
Disease class Disease CUIs Genes
COPD




Nutritional and Metabolic Diseases Diabetes 332 757
Metabolic syndrome 4 47
Obesity 47 313
Musculoskeletal Diseases Muscle weakness 8 65
Osteoporosis 37 128
Respiratory Tract Diseases Pulmonary
hypertension
22 57
Lung cancer 81 1369
Sleep apnea 19 27
Hemic and Lymphatic Diseases Anemia 5 13
Polycythemia 11 16
Cardiovascular Diseases Atrial fibrillation 21 74





Pathological Conditions, Signs and
Symptoms
Cachexia 8 19
Behavior and Behavior Mechanisms Depression 105 160
Diseases are classified according the MeSH disease herarchy.
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distinct clinical manifestations [9,11].
In this study, we sought to test the shared component
hypothesis in COPD. Under this hypothesis, the multi-
morbidities of COPD most frequently seen in the clinic
would be related between them and with COPD at the
molecular level by common genes, proteins and bio-
logical pathways. To this end, we used a network medi-
cine approach that included: (1) data mining of the
diseasome (or disease network), the interactome (as de-
fined by a protein-protein interaction (PPI) network) to
enrich this diseasome and the tobacco smoking expo-
some (representing the exposure to tobacco smoke che-
micals, the main risk factor for COPD); and, (2) a
functional analysis to identify the biological pathways
potentially involved in COPD multimorbidity. Our find-
ings indicate that the most prevalent COPD multimor-
bidities are likely to be related at the molecular level,
and highlight some previously overlooked pathways that
might contribute to explain their co-occurrence. Re-
markably, the results here presented propose new hy-




Clinical experts selected 16 prevalent diseases frequently
associated with COPD (Table 1) [12-14]. Their Concept
Unique Identifiers (CUI) were obtained from the Unified
Medical Language System (UMLS)Metathesaurus (Figure 1
panel A) [15]. After manual curation, the disease vocabu-
lary used in the analysis included a mean of 59 CUIs (range
4–332) for each disease (and 14 CUIs for COPD, 33 for
emphysema and 16 for chronic bronchitis (Additional
file 1: Table S1)).
Building the COPD diseasome
The “diseasome” is a network representation of the associ-
ations between diseases, where two of them are linked if
they share alterations in genes or proteins, or if the altered
proteins are connected in the interactome (9) (Figure 2).
DisGeNET (version 2.0), a database that integrates infor-
mation on human diseases and their associated genes
from various public databases and from the biomedical lit-
erature [16], was used to collect information on proteins
altered in COPD and the multimorbidities studied here
using our disease vocabulary (Figure 1 panel B). The hu-
man interactome was obtained by combining PPI informa-
tion from the Pathway Commons database [17] (http://
www.pathwaycommons.org/), gathering biological path-
way information collected from public pathway databases
and HIPPIE [18] (http://cbdm.mdc-berlin.de/tools/hippie/
information.php), a human PPI database that integrates
multiple experimental PPI datasets (Figure 1 panel B).When building the diseasome based on proteins in
common between two diseases, it could be argued that it
is more likely to find shared proteins among diseases
that have been characterized more extensively. In order
to minimize this bias when estimating the strength of
the association between two given diseases (dis1 and
dis2) in the diseasome (Figure 1 panel C), we calculated
the Molecular Comorbidity Index (MCI) as defined by:
MCIdis1;dis2 ¼ j proteinsdis1∩ proteinsdis2ð Þ
∪ proteinsdis1→dis2∪ proteinsdis2→dis1j
proteinsdis1∪ proteinsdis2j j
where proteinsdis1 and proteinsdis2 are the proteins asso-
ciated with disease 1 and 2, respectively, proteinsdis1→dis2
are those proteins associated with disease 1 that inter-
act with those associated with disease 2 (and vice versa
(proteinsdis2→dis1)), ∩ is the intersection operator and ∪
is the union operator between two sets of elements
(proteinsdis1 and proteinsdis2). The sets resulting in both
numerator and denominator are written within vertical
bars to indicate their cardinality (number of element).
Figure 1 Schematic representation of the methodology applied in this study. Panel A: Clinical experts selected prevalent multimorbidities in
COPD, and manually curated lists of Concept Unique Identifiers (CUI) obtained from the Unified Medical Language System (UMLS) Metathesaurus
to extract relevant synonyms for each disease. Panel B: DisGeNet was used to obtain gene-disease associations and every protein encoded by
the selected gene was mapped into a protein-protein network created from HIPPIE and Pathway Commons databases. Panel C: Gene-disease
associations and protein-protein interaction information were combined to build the diseasome. The Molecular Comorbidity Index estimates
the strength of association between 2 diseases based on shared genes and proteins. The genes and proteins targeted by cigarette smoke
components were obtained from CTD. Panel D: A functional enrichment analysis was performed to identify the most likely pathways that could
lead to the development of a specific multimorbidity and Panel E: pathway similarity between multimorbidities was assessed calculating the
Jaccard Coefficient.
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To identify the most significant biological functions of the
shared proteins between two diseases, a functional enrich-
ment analysis with biological pathways from Reactome was
performed [19]. The Reactome database contains informa-
tion on genes, proteins and their participation in biological
pathways. In our analysis, we used the R package Reacto-
mePA, which uses the hypergeometric function to test the
significance of annotations [20]. Significant annotations
were those with q-values≤ 0.05 (the q-value corresponds to
the false discovery rate (FDR), an adjusted equivalent to the
standard statistical p-value incorporated in ReactomePA).
To evaluate the number of biological pathways shared by
COPD multimorbidities, we used the Jaccard coefficient,
which is defined as:
Jaccard coefficientmultimorbidity1;multimorbidity2









where multimorbidity1 and multimorbidity2 represent
two pairs of COPD multimorbidities (for instance lung
cancer-COPD and diabetes-COPD) whereas pathways
of multimorbidity1 and pathways of multimorbidity2
represent the biological pathways in which the proteins
associated with the pairs multimorbidity1 and multi-
morbidity2 participate respectively. The Jaccard Coeffi-
cient is a measure of the degree of similarity between
two COPD multimorbidities (for instance lung cancer-
COPD and diabetes-COPD) at the level of biological
pathways. Results were visualized as heat-maps using
Gitools [21].
Exploration of the tobacco exposome
Using the Comparative Toxicogenomics Database (CTD),
a database gathering information about gene/protein and
chemical interactions, we investigated if the genes and
proteins shared by COPD multimorbidities were potential
biological targets for chemical compounds present in the
tobacco smoke [22,23].
Figure 2 Building the diseasome. Panel A: four different diseases (D1, D2, D3 and D4) can share relevant genes (GA, GB, GC) (left graph). Using
this information, a diseasome can be built where D1 shares GA with D2, and D3 shares GC with D4 (right). Panel B: The genetic information
identified above can be complemented with the interactome to build the diseasome, where the protein encoded by GB (PB) interacts with that
encoded by GC (PC) (left graph). For further explanations, see text.
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COPD is linked through genes and proteins to its
comorbid diseases
COPD has been associated in the literature with alter-
ations in 187 genes, whereas the number of genes asso-
ciated with the 16 comorbidities analyzed here range
from 19 (cachexia) to 1,369 (lung cancer) (Table 1 and
Additional file 2: Figure S1 in the online data supple-
ment). As explained in Figure 2, we used this knowledge
on the genetic basis of these diseases in combination
with data obtained from the interactome to build the
COPD diseasome, and found that all 16 comorbidities
studied here can be connected through shared genes
and/or proteins that interact within cellular networks.
Figure 3 illustrates how COPD and anemia are linked
through this network of interactions. Both diseases are
directly associated to 3 proteins in common, SOD2, TP53
and TNF (green nodes in Figure 3), and are also connected
through the interactions between 22 proteins (pink and lila
nodes in Figure 3). These bridging proteins constitute po-
tential candidates to explain the association between
COPD and anemia that should be further investigated.
In the COPD diseasome, the number of shared genes or
proteins ranged from less than 100 (COPD and anemia) to
more than 700 (COPD and lung cancer) (Figure 4). In
terms of the Molecular Comorbidity Index (MCI), that is
an indicator of the strength of the association betweentwo diseases normalized for those better studied (for in-
stance, lung cancer, see Methods), ischemic heart dis-
ease ranked first in the list of COPD multimorbidities
(approximately 400 shared proteins with a MCI of 0.53),
followed by lung cancer, stroke and diabetes. The fre-
quency distribution of the MCI (Figure 4) paralleled
that reported in the literature for the multimorbidities
studied here [10,24,25].
The proposed network medicine workflow not only al-
lows a global analysis of the genes and proteins support-
ing a particular multimorbidity (see next sections), but
it also provides detailed information on specific genes
and their association to the multimorbid diseases under
study. For example, the gene ADRB2, is associated to sev-
eral multimorbidities: COPD with cardiovascular diseases
(atrial fibrillation, heart failure, ischemic heart disease and
stroke), and with diabetes, lung cancer and obesity. Inter-
estingly, the protein encoded by this gene has been shown
to participate in smooth muscle relaxation in bronchi
resulting in a facilitated respiration [26]; in blood vessels,
it dilates coronary and skeletal muscle arteries [27] and it
also contributes to insulin secretion from pancreas [28].
ADRB2 has been the focus of pharmacogenomics studies
in COPD: several polymorphisms of this gene have been
shown to influence patient response to bronchodilators
treatment [29]. A recent study showed a significant cor-
relation between the R16G polymorphism with COPD
Figure 3 COPD and anemia are connected at the molecular level. The network represents the association between both diseases and
proteins (thin edges) and the association between the proteins (thick edges). We show in green the proteins that are directly associated to both
COPD and anemia (SOD2, TP53 and TNF). The pink and lila nodes are proteins associated to COPD or anemia, respectively, but also serve as
bridges between both diseases because these proteins interact within the interactome.
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1 second) in a Greek population [30]. Interestingly, the
R16G–Q27E haplotype has been shown to be associated
with glucose tolerance and insulin sensitivity in obese
postmenopausal women [27]. Thus, this polymorphism
might influence both bronchodilator response and glu-
cose tolerance in specific patient populations, constitut-
ing a potential link to explain the association between
COPD and diabetes.
Another study in a Danish population showed that the
ADRB2 T164I polymorphism is associated with a reduced
lung function and an increased risk of COPD in the gen-
eral population [31]. This polymorphism is also associatedFigure 4 Number of proteins shared between COPD and each of the
MCIs (line). The percentages shown on top of bars indicate the proportion
present in tobacco smoke as per the CTD. For further explanations, see texwith increased blood pressure, higher frequency of hyper-
tension and increased risk of ischemic heart disease
amongst women in the general population [26]. Thus, the
ADRB2 T164I polymorphism could explain the associ-
ation between COPD and cardiovascular diseases.
Further analysis using haplotype frequencies indicated
that haplotypes G16-Q27-I164 and (non-G16-Q27)-
T164, as compared to the reference haplotype G16-Q27-
T164, were significantly associated with a decreased risk
of myocardial infarction [32]. In summary, the ADRB2
gene represents an interesting candidate to explain the
multimorbidity of COPD with diabetes, obesity and is-
chemic heart disease.multimorbidities studied here (bars) and their corresponding
of shared proteins targeted by, at least, one chemical compound
t.
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the COPD diseasome
To identify the most relevant biological functions of the
genes and proteins shared by the COPD diseasome, we
performed a functional enrichment analysis with biological
pathways from Reactome on the set of common proteins,
as detailed in the Methods section. Significant annotations
were those with q-values≤ 0.05, and results are visualized
here as heat-maps. We observed that “Innate immune re-
sponse” pathways were enriched in almost all of the multi-
morbidity pairs studied, particularly in those of COPD
with diabetes, osteoporosis, lung cancer, heart failure or
ischemic heart disease (Additional file 3: Figure S2 in
the Supporting information). “Adaptive immune response”
pathways showed a similar pattern: they were also
enriched in all the pairs with the exception of those of
COPD with metabolic syndrome, anemia, sleep apnea and
cachexia (Additional file 4: Figure S3 in the online data
supplement). Likewise, with the exception of the pair pul-
monary hypertension-COPD, “Apoptosis” pathways and
related signaling events, such as “TNF signaling” or “Death
receptor signaling” were also involved in most multimor-
bidity pairs (Additional file 5: Figure S4 in the online
data supplement). Interestingly, proteins involved in the
“Nitric oxide metabolism” pathway were associated with
COPD multimorbidities involving the cardiovascular
system (atrial fibrillation, heart failure, ischemic heart
disease and stroke), metabolic diseases (diabetes, meta-
bolic syndrome), osteoporosis, pulmonary hypertension,
lung cancer and depression (Additional file 6: Figure S5
in the online data supplement). “Hemostasis” pathways,
including “Platelet activation, signaling and aggregation”
were also enriched in all the pairs studied (Figure 5). Fi-
nally, “Cell cycle” pathways were enriched in lung
cancer-COPD, diabetes-COPD and, surprisingly, in
depression-COPD (Additional file 7: Figure S6 in the
online data supplement).
Overlap of identified biological pathways in the COPD
diseasome
To explore the degree of similarity between two COPD
multimorbidities (for instance lung cancer-COPD and
diabetes-COPD) at the level of biological pathways, we
used the Jaccard coefficient (see Methods). We found
the highest Jaccard coefficient values among pairs of
COPD and several CVDs, including heart failure, ische-
mic heart disease and stroke, which share approximately
50% of the involved pathways (Figure 6). Likewise, the
level of pathway coincidence was also considerable be-
tween pairs of CVD-COPD and pairs of COPD with nu-
tritional and metabolic diseases. More surprisingly was
the observation of a relatively high Jaccard coefficient
between CVD-COPD pairs and osteoporosis-COPD, as
well as that lung cancer-COPD and diabetes-COPD thatshowed a pathway similarity of 48% (lung cancer and
diabetes without taking into account COPD showed only
35% of pathway similarity). Albeit to a lesser degree, nu-
tritional and metabolic diseases-COPD and musculoskel-
etal diseases-COPD groups present pathway similarities
as well. Other interesting associations that emerged from
this analysis included the overlap between depression-
COPD and diabetes-COPD, and between depression-
COPD and heart failure-COPD. Finally, it was also of
interest to note that the biological pathways involved in
some comorbid disease-COPD pairs were almost unre-
lated to those of others (for instance, anemia-COPD,
cachexia-COPD, sleep-apnea-COPD or polycythemia-
COPD) (Figure 6). All in all, these observations highlight
interesting associations between COPD multimorbidities
at the biological pathway level.
Exploration of the tobacco exposome
According to the CTD [33], the 106 tobacco smoke che-
micals present in the tobacco smoke [22,23] target an
average of 69% of the proteins shared by COPD and the
multimorbidities shown in Figure 4 (see complete data
set on Additional file 8: Table S2 in the online data sup-
plement). For instance, 468 out of the 759 (61.7%) pro-
teins shared by COPD and lung cancer are known
targets of at least one compound present in tobacco
smoke. This proportion was even higher (72%) in the
case of stroke with COPD. This is not surprisingly since
tobacco smoke is a main risk factor of COPD, CVD and
lung cancer. Yet, even in multimorbidities that, at first
glance, might seem unrelated to smoking, such as meta-
bolic syndrome, diabetes or anemia, we also found a
high percentage of shared proteins that are established
targets of tobacco smoke compounds in the CTD, which
provides potential candidates to investigate the role of
tobacco smoke compounds in COPD multimorbidities.
Discussion
The network medicine analysis of COPD multimorbid-
ities presented here shows that 16 prevalent COPD mul-
timorbidities often share genes, proteins and biological
pathways with COPD, and that many of these proteins
are targets for tobacco smoke chemicals. Overall, these
observations support the shared component hypothesis
of the COPD diseasome, and allow the identification of
specific molecular links (genes, proteins, biological path-
ways) between COPD and its comorbid diseases.
The vast amount of information available today in differ-
ent areas of science makes it necessary to properly mine
and connect it in a network of information that allows the
generation of new knowledge. This strategy has the poten-
tial to bring out new hypotheses that are not self-evident
when using more traditional scientific approaches. In
the present study, we performed an integrative mining
Figure 5 Hemostasis Biological pathway for COPD multimorbidities. The heat-map represents the enrichment of different pathways belonging
to the Hemostasis category. Each cell of the heatmap is colored according to the q-value of the pathway enrichment for each COPD multimorbidity,
where the most significant signals are from red (q-value ~ 0) to yellow (q-value < 5%). When a pathway is not statistically significant (q-value > 5%), the
cell is left blank.
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databases (HIPPIE, Pathway Commons, Reactome, CTD,
DisGeNET) and experts in COPD multimorbidities (AF,
RF, JR, BC, AA, JG) and bioinformatics (SG, JP, FS, LIF),
who participated in the analysis phases. Future studies will
have to explore experimentally the new hypotheses gener-
ated in this analysis.
COPD is a paradigmatic gene-environment disease
since tobacco smoking, and other environmental factors,
are well established risk factors, but not all exposed sub-
jects develop the disease, suggesting a role for the gen-
etic background of the exposed individual [34]. The fact
that COPD clusters in families further supports this lat-
ter aspect [35]. Multimorbidities frequently occur inCOPD patients and have a very significant impact in the
natural history of the disease [34]. Yet, the precise
pathogenic mechanism(s) underlying this COPD disea-
some are unclear. To our knowledge, this is the first
study to use a comprehensive and integrative bioinfor-
matic approach to investigate the so-called shared com-
ponent hypothesis [7-9] as a pathogenic mechanism of
COPD multimorbidities.
Our findings suggest that the most prevalent COPD
multimorbidities are related at the molecular level, and
highlight some previously overlooked pathways that
might contribute to explain their co-occurrence. In this
context, that COPD shares certain molecular mecha-
nisms with cardiovascular diseases or lung cancer is
Figure 6 Similarities between COPD multimorbidities. Each cell
is colored according to the value of the Jaccard coefficient that
represents the degree of similarity between two COPD
multimorbidities, considering biological pathways. For further
explanations, see text.
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these mechanisms with depression or diabetes is more
intriguing. Likewise, it is of note that proteins involved
in the “Nitric Oxide Metabolism” pathway were associ-
ated with multimorbidities involving the cardiovascular
system, but also with metabolic diseases, as well as with
osteoporosis, pulmonary hypertension, lung cancer and
depression (Additional file 6: Figure S5 in the online
data supplement).
Some of the shared biological pathways identified, in-
cluding those related to the immune response, apoptosis,
cytokine signaling or endothelial function, are well de-
scribed in the field, albeit they serve as a proof of con-
cept for the methodology employed. Yet, our analysis
has also identified others pathways not previously related
to COPD multimorbidities, such as hemostasis in multi-
morbidities other than cardiovascular disorders, or alter-
ations in cell cycle in the COPD-depression association.
Of note, it has been previously reported that increases in
platelet activation and aggregation augment the risk of
patients with depression to suffer CVD [35]. It is also
worth noting that abnormalities in adult neurogenesis
has been implicated in the etiology of depression [36,37]
thus indicating that a disruption of cell cycle pathways
in neural cells might underlie the observed association
of COPD with depression. These new and unexpected
findings require now to be tested experimentally but, all
in all, our observations suggest that the multimorbidities
in COPD should probably be understood as a networkof clinical manifestations (i.e., diseasome) that expresses
a complex interaction between a number of environ-
mental, biological and genetic (and epigenetic) governing
factors [2,3].
Tobacco smoke is the main risk factor of both COPD
and some of its associated diseases [38]. According to
CTD [33], chemicals contained in the tobacco smoke tar-
get an average of 69% of the proteins studied (Figure 3).
This is not surprising for diseases like CVD or lung cancer,
where tobacco smoking is a well-established risk factor,
but it may open new avenues for research in other comor-
bid diseases.
Strengths and limitations
The novelty, as well as the unbiased and integrative na-
ture of our scientific approach, is a clear strength of our
analysis. However, some limitations are worth noting.
The most relevant one is that our analysis depends on
the scientific information that is available and recorded
in public databases, such as Medline, Reactome and
other repositories of biological data. Further, due to limi-
tations in database development and curation, many of
such databases are likely to be incomplete [39]. Hence,
the results of our analysis should be mostly regarded as
hypothesis generators requiring experimental validation.
Conclusions
Our network medicine analysis identified plausible mo-
lecular connections in the COPD diseasome (through
genes, proteins and biological pathways), and showed
that many of them are targets of the tobacco exposome,
proposing new areas of research for understanding the
molecular underpinning of COPD multimorbidities.
Additional files
Additional file 1: Table S1. List of the UMLS CUIs for each disease
represented in Table 1.
Additional file 2: Figure S1. Venn diagram representing the genes
associated to COPD, chronic bronchitis and emphysema, and the genes
shared by these diseases. One hundred eighty seven genes are
associated to the three diseases in the DisGeNET database [16].
Additional file 3: Figure S2. Innate Immune System Biological pathway
for COPD multimorbidities. The heat-map represents the enrichment of
different pathways belonging to the “Innate Immune System” category.
Each cell of the heatmap is colored according to the q-value of the
pathway enrichment for each COPD multimorbidity, where the most
significant signals are from red (q-value ~ 0) to yellow (q-value < 5%).
When a pathway is not statistically significant (q-value > 5%), the cell is
left blank.
Additional file 4: Figure S3. Adaptive Immune System Biological
pathway for COPD multimorbidities. The heat-map represents the
enrichment of different pathways belonging to the “Adaptive Immune
System” category. Each cell of the heatmap is colored according to the
q-value of the pathway enrichment for each COPD multimorbidity, where
the most significant signals are from red (q-value ~ 0) to yellow (q-value
< 5%). When a pathway is not statistically significant (q-value > 5%), the
cell is left blank.
Grosdidier et al. Respiratory Research 2014, 15:111 Page 9 of 10
http://respiratory-research.com/content/15/1/111Additional file 5: Figure S4. Apoptosis Biological pathway for COPD
multimorbidities. The heat-map represents the enrichment of different
pathways belonging to the “Apoptosis” category. Each cell of the
heatmap is colored according to the q-value of the pathway enrichment
for each COPD multimorbidity, where the most significant signals are
from red (q-value ~ 0) to yellow (q-value < 5%). When a pathway is not
statistically significant (q-value > 5%), the cell is left blank.
Additional file 6: Figure S5. Nitric Oxide Metabolism Biological
pathway for COPD multimorbidities. The heat-map represents the
enrichment of different pathways belonging to the “Nitric Oxide
Metabolism” category. Each cell of the heatmap is colored according to
the q-value of the pathway enrichment for each COPD multimorbidity,
where the most significant signals are from red (q-value ~ 0) to yellow
(q-value < 5%). When a pathway is not statistically significant (q-value > 5%),
the cell is left blank.
Additional file 7: Figure S6. Cell Cycle Biological pathway for COPD
multimorbidities. The heat-map represents the enrichment of different
pathways belonging to the “Cell Cycle” category. Each cell of the
heatmap is colored according to the q-value of the pathway enrichment
for each COPD multimorbidity, where the most significant signals are
from red (q-value ~ 0) to yellow (q-value < 5%). When a pathway is not
statistically significant (q-value > 5%), the cell is left blank.
Additional file 8: Table S2. List of tobacco smoke compounds used in
this study and the genes that they target.
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